Evotec (EVO) is attracting potential takeover interest from Halozyme Therapeutics (HALO), Eyk Henning of Bloomberg reports, citing people familiar with the matter. Halozyme has recently expressed interest in acquiring Evotec at about EUR 11 per share, which would represent a 27% premium to Evotec’s closing price on Thursday and value the company at nearly $2.1B, sources told Bloomberg. Considerations are at an early stage and there’s no certainty they will lead to a deal, they added. Shares of Evotec jumped 10% to $5.02 following the report while Halozyme dropped 3% to $56.60.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVO:
- Evotec price target lowered to EUR 11.60 from EUR 12 at RBC Capital
- Evotec rallies after Bloomberg says Triton weighing takeover bid
- Evotec Reports Strategic Growth Amidst Revenue Challenges
- Evotec AG Strengthens Alliances Amidst Revenue Challenges
- Is EVO a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
